The predictive and prognostic significance of c-erb-B2, EGFR, PTEN, mTOR, PI3K, p27, and ERCC1 expression in hepatocellular carcinoma

Hepatitis Monthly

Volumn 12, Issue 10 HCC, 2012, Pages 100-109

  Bassullu, Nuray ^a   Turkmen, Ilknur ^a   Dayangac, Murat ^b   Korkmaz, Pinar Yagiz ^b   Yasar, Reyhan ^b   Akyildiz, Murat ^a   Yaprak, Onur ^b   Tokat, Yaman ^b   Yuzer, Yildiray ^b   Dogusoy, Gulen Bulbul ^b  

^a ISTANBUL BILIM UNIVERSITY   (Turkey)

^b FLORENCE NIGHTINGALE HOSPITAL   (Turkey)

Author keywords

Carcinoma; Hepatocellular; Immunohistochemistry

Indexed keywords

CYCLOSPORIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P27; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER CELL CARCINOMA; LYMPH NODE METASTASIS; MALE; MULTIPLE CANCER; ONCOGENE NEU; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR VOLUME;

EID: 84871493808     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.7492     Document Type: Article

References (47)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer. 1999;80(6):827-41.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.
3. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M. Cancer Incidence in Five Continents. Vol. IX, IARC Scientific Publications No. 160, Lyon, IARC,Publications No. 160. 2007.
4. Rosai J. Rosai and Ackerman's Surgical Pathology 10th edition. Edinburgh:, Vol 1, pp 944-7. Elsevier; 2011.
5. Yu MW, Chen CJ, Luo JC, Brandt-Rauf PW, Carney WP, Santella RM. Correlations of chronic hepatitis B virus infection and cigarette smoking with elevated expression of neu oncoprotein in the development of hepatocellular carcinoma. Cancer Res. 1994;54(19):5106-10.
6. Vlasoff DM, Baschinsky DY, De Young BR, Morrison CD, Nuovo GJ, Frankel WL. C-erb B2 (Her2/neu) is neither overexpressed nor amplified in hepatic neoplasms. Appl Immunohistochem Mol Morphol. 2002;10(3):237-41.
7. Ito Y, Takeda T, Sakon M, Tsujimoto M, Higashiyama S, Noda K, et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer. 2001;84(10):1377-83.
8. Baxevanis CN, Sotiropoulou PA, Sotiriadou NN, Papamichail M. Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy. Cancer Immunol Immunother. 2004;53(3):166-75.
9. Brunt EM, Swanson PE. Immunoreactivity for c-erbB-2 oncopeptide in benign and malignant diseases of the liver. Am J Clin Pathol. 1992;97(5 Suppl 1):S53-61.
10. Collier JD, Guo K, Mathew J, May FE, Bennett MK, Corbett IP, et al. c-erbB-2 oncogene expression in hepatocellular carcinoma and cholangiocarcinoma. J Hepatol. 1992;14(2-3):377-80.
11. Nakopoulou L, Stefanaki K, Filaktopoulos D, Giannopoulou I. C-erb-B-2 oncoprotein and epidermal growth factor receptor in human hepatocellular carcinoma: an immunohistochemical study. Histol Histopathol. 1994;9(4):677-82.
12. Tang Z, Qin L, Wang X, Zhou G, Liao Y, Weng Y, et al. Alterations of oncogenes, tumor suppressor genes and growth factors in hepatocellular carcinoma: with relation to tumor size and invasiveness. Chin Med J (Engl). 1998;111(4):313-8.
13. Altimari A, Fiorentino M, Gabusi E, Gruppioni E, Corti B, D'Errico A, et al. Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours. Dig Liver Dis. 2003;35(5):332-8.
14. Xian ZH, Zhang SH, Cong WM, Wu WQ, Wu MC. Overexpression/ amplification of HER-2/neu is uncommon in hepatocellular carcinoma. J Clin Pathol. 2005;58(5):500-3.
15. Niu ZS, Wang M. Expression of c-erbB-2 and glutathione S-transferase-pi in hepatocellular carcinoma and its adjacent tissue. World J Gastroenterol. 2005;11(28):4404-8.
16. Lee TY, Kim KT, Han SY. Expression of ErbB receptor proteins and TGF-alpha during diethylnitrosamine-induced hepatocarcinogenesis in the rat liver. Korean J Hepatol. 2007;13(1):70-80.
17. Liu J, Ahiekpor A, Li L, Li X, Arbuthnot P, Kew M, et al. Increased expression of ErbB-2 in liver is associated with hepatitis B x antigen and shorter survival in patients with liver cancer. Int J Cancer. 2009;125(8):1894-901.
18. Zhang JK, Pan PL, Wu YM, Xiao JJ, Peng JW. [Expression of HER-2/ neu oncogene in hepatocellular carcinoma and the clinical implications]. Nan Fang Yi Ke Da Xue Xue Bao. 2010;30(2):326-8.
19. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997;15(4):356-62.
20. Hu TH, Huang CC, Lin PR, Chang HW, Ger LP, Lin YW, et al. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/ TEP1 in hepatocellular carcinoma. Cancer. 2003;97(8):1929-40.
21. Wu SK, Wang BJ, Yang Y, Feng XH, Zhao XP, Yang DL. Expression of PTEN, PPM1A and P-Smad2 in hepatocellular carcinomas and adjacent liver tissues. World J Gastroenterol. 2007;13(34):4554-9.
22. Chen JS, Wang Q, Fu XH, Huang XH, Chen XL, Cao LQ, et al. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. Hepatol Res. 2009;39(2):177-86.
23. Zhou L, Huang Y, Li J, Wang Z. The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol. 2010;27(2):255-61.
24. Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 2008;135(6):1972-83, 83 e1-11.
25. Matsuda Y. Molecular mechanism underlying the functional loss of cyclindependent kinase inhibitors p16 and p27 in hepatocellular carcinoma. World J Gastroenterol. 2008;14(11):1734-40.
26. Huang X, Qian X, Cheng C, He S, Sun L, Ke Q, et al. Expression of Pirh2, a p27(Kip1) ubiquitin ligase, in hepatocellular carcinoma: correlation with p27(Kip1) and cell proliferation. Hum Pathol. 2011;42(4):507-15.
27. Sarfraz S, Hamid S, Ali S, Jafri W, Siddiqui AA. Modulations of cell cycle checkpoints during HCV associated disease. BMC Infect Dis. 2009;9:125.
28. Ito Y, Matsuura N, Sakon M, Miyoshi E, Noda K, Takeda T, et al. Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence. Hepatology. 1999;30(1):90-9.
29. He S, Lu M, Xue W, Wang Y, Zhao Y, Gao S, et al. Phosphorylated p27Kip1 on Thr157 is an important prognosis in human hepatocellular carcinoma in vivo and in vitro. Med Oncol. 2011;28(1):94-104.
30. Mitselou A, Karapiperides D, Nesseris I, Vougiouklakis T, Agnantis NJ. Altered expression of cell cycle and apoptotic proteins in human liver pathologies. Anticancer Res. 2010;30(11):4493-501.
31. Tretiakova MS, Shabani-Rad MT, Guggisberg K, Hart J, Anders RA, Gao ZH. Genomic and immunophenotypical differences between hepatocellular carcinoma with and without cirrhosis. Histopathology. 2010;56(6):683-93.
32. Shehata MA, Nosseir HR, Nagy HM, Farouk G. Cyclin dependent kinase inhibitor p27(kip1) expression and subcellular localization in relation to cell proliferation in hepatocellualr carcinoma. Egypt J Immunol. 2006;13(1):115-30.
33. Fautrel A, Andrieux L, Musso O, Boudjema K, Guillouzo A, Langouet S. Overexpression of the two nucleotide excision repair genes ERCC1 and XPC in human hepatocellular carcinoma. J Hepatol. 2005;43(2):288-93.
34. Ueda S, Shirabe K, Morita K, Umeda K, Kayashima H, Uchiyama H, et al. Evaluation of ERCC1 expression for cisplatin sensitivity in human hepatocellular carcinoma. Ann Surg Oncol. 2011;18(4):1204-11.
35. Turhal NS, Bas E, Er O, Aliustaoglu M, Seber S, Dane F, et al. ERCC1 is not expressed in hepatocellular cancer: A turkish oncology group, gastrointestinal oncology subgroup study. J Buon. 2010;15(4):794-6.
36. Salerno F, Merli M, Cazzaniga M, Valeriano V, Rossi P, Lovaria A, et al. MELD score is better than Child-Pugh score in predicting 3-month survival of patients undergoing transjugular intrahepatic portosystemic shunt. J Hepatol. 2002;36(4):494-500.
37. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33(6):1394-403.
38. Ruby SG. Protocol for the examination of specimens from patients with hepatocellular carcinoma and cholangiocarcinoma, including intrahepatic bile ducts. Cancer Committee of the College of American Pathologists. Arch Pathol Lab Med. 2000;124(1):41-5.
39. Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 2012;13(1):33-42.
40. Friboulet L, Barrios-Gonzales D, Commo F, Olaussen KA, Vagner S, Adam J, et al. Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC. Clin Cancer Res. 2011;17(17):5562-72.
41. Song CH, Park SY, Eom KY, Kim JH, Kim SW, Kim JS, et al. Potential prognostic value of heat-shock protein 90 in the presence of phosphatidylinositol-3-kinase overexpression or loss of PTEN, in invasive breast cancers. Breast Cancer Res. 2010;12(2):R20.
42. Alacacioglu A, Somali I, Simsek I, Astarcioglu I, Ozkan M, Camci C, et al. Epidemiology and survival of hepatocellular carcinoma in Turkey: outcome of multicenter study. Jpn J Clin Oncol. 2008;38(10):683-8.
43. Bassullu N, Turkmen I, Yaprak O, Dayangac M, Demirbas T, Guler N, et al. General evaluation of hepatectomy and hepatocellular carcinoma cases. Turk Patoloji Derg. 2011;27(3):221-9.
44. Tanaka H. [Immunohistochemical studies on epidermal growth factor receptor in hepatocellular carcinoma]. Nihon Shokakibyo Gakkai Zasshi. 1991;88(2):138-44.
45. Buckley AF, Burgart LJ, Sahai V, Kakar S. Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. Am J Clin Pathol. 2008;129(2):245-51.
46. El-Bassiouni A, Nosseir M, Zoheiry M, El-Ahwany E, Ghali A, El-Bassiouni N. Immunohistochemical expression of CD95 (Fas), c-myc and epidermal growth factor receptor in hepatitis C virus infection, cirrhotic liver disease and hepatocellular carcinoma. APMIS. 2006;114(6):420-7.
47. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355(10):983-91.